Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.66 USD
Change Today -0.03 / -4.35%
Volume 39.8K
KOOL On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:00 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

cesca therapeutics inc (KOOL) Snapshot

Open
$0.72
Previous Close
$0.69
Day High
$0.72
Day Low
$0.66
52 Week High
09/2/14 - $1.41
52 Week Low
08/5/15 - $0.58
Market Cap
26.7M
Average Volume 10 Days
40.3K
EPS TTM
$-0.32
Shares Outstanding
40.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CESCA THERAPEUTICS INC (KOOL)

cesca therapeutics inc (KOOL) Related Bloomberg News

View More Bloomberg News

cesca therapeutics inc (KOOL) Related Businessweek News

No Related Businessweek News Found

cesca therapeutics inc (KOOL) Details

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks platform, a proprietary stem cell therapy point-of-care kit systems for treating vascular and orthopedic indications, which integrates various indication specific systems, such as cell harvesting, cell processing and selection, cell diagnostics, and cell delivery; and CellWerks platform for the optimal processing of targeted cells used in the treatment of oncological and hematological disorders. The company also offers MarrowXpress system, which isolates and concentrates stem cells from bone marrow; AXP System, a medical device with a disposable bag set that isolates and retrieves stem cells from umbilical cord blood; and BioArchive System, a robotic cryogenic medical device, which is used to cryopreserve and archive stem cells for future transplant and treatment. In addition, the company provides Res-Q 60 bone marrow concentrate, a centrifuge-based disposable device used for the isolation and extraction of specific stem cell populations from bone marrow; and Res-Q 60 platelet rich plasma (PRP) for the preparation of autologous PRP from a small sample of blood at the point of care. Further, it offers cell manufacturing and banking services. The company sells its products in the United States; Hong Kong, China, and other Asian countries; Europe; South America; and internationally. It was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

95 Employees
Last Reported Date: 09/29/14
Founded in 1986

cesca therapeutics inc (KOOL) Top Compensated Officers

President and Director
Total Annual Compensation: $136.0K
Chief Biologist and Senior Vice President
Total Annual Compensation: $114.0K
Vice President of Corporate Development & Sci...
Total Annual Compensation: $240.0K
Vice President of Manufacturing and IT
Total Annual Compensation: $257.0K
Advisor
Total Annual Compensation: $449.0K
Compensation as of Fiscal Year 2014.

cesca therapeutics inc (KOOL) Key Developments

Cesca Therapeutics Announces Compliance With Nasdaq Stock Market Under Listing Rule 5250(c)(1)

Cesca Therapeutics, Inc. announced that the Company has received a letter from the office of Nasdaq Listings Qualifications dated June 24, 2015, indicating that the Company complies with Nasdaq Listing Rule 5250(c)(1) because the Company has filed its Forms 10-Q for the periods ended December 31, 2014 and March 31, 2015 with the U.S. Securities and Exchange Commission.

Cesca Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Cesca Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net revenues of $4,042,000 against $4,038,000 a year ago. Loss from operations was $4,836,000 against $1,859,000 a year ago. Net loss was $4,811,000 against $1,859,000 a year ago. Basic and diluted net loss per was $0.12 against $0.07 a year ago. Adjusted EBITDA loss was $4,083,000 against $1,422,000 a year ago. The increase in the Adjusted EBITDA loss of $2.7 million and the increase in the net loss of $2.9 million were due to investments in the development and advancement of clinical programs and legal and professional costs associated with patent litigation and to analyze and begin to remediate material weakness in governance practices. Revenues for AXP disposables increased over the prior year comparable period as shipments to one of Asia distributors increased. This increase was offset by a decrease associated with BioArchive devices as shipped two in the current quarter versus five in the prior year comparable period. For the nine months, the company reported net revenues of $12,340,000 against $12,150,000 a year ago. Loss from operations was $12,476,000 against $5,761,000 a year ago. Net loss was $12,478,000 against $5,761,000 a year ago. Basic and diluted net loss per was $0.31 against $0.28 a year ago. Net cash used in operating activities was $9,315,000 against $6,096,000 a year ago. Capital expenditures were $544,000 against $326,000 a year ago. Adjusted EBITDA loss was $10,380,000 against $4,712,000 a year ago.

Cesca Therapeutics Inc. to Report Q3, 2015 Results on Jun 23, 2015

Cesca Therapeutics Inc. announced that they will report Q3, 2015 results at 10:00 AM, GMT Standard Time on Jun 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KOOL:US $0.66 USD -0.03

KOOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.13 USD 0.00
Bioheart Inc $0.0032 USD 0.00
Caladrius Biosciences Inc $1.64 USD -0.06
Cytori Therapeutics Inc $0.35 USD -0.0267
Nuo Therapeutics Inc $0.05 USD -0.023
View Industry Companies
 

Industry Analysis

KOOL

Industry Average

Valuation KOOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CESCA THERAPEUTICS INC, please visit www.cescatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.